drugset / Trial / NCT00783484
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects
RandomizedCrossoverDouble-blindTreatment
Summary
First in human study to evaluate the safety, tolerability, and pharmacokinetics of PF-03716539. The potential of PF-03716539 to increase the concentrations of midazolam, darunavir and maraviroc will also be evaluated.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-05
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darunavir | Small molecule | 600 mg | — |
| Subject | Maraviroc | Other / unclassified | 150 mg | — |
| Subject | Maraviroc | Other / unclassified | 225 mg | — |
| Subject | Midazolam | Small molecule | 1 mg | Intravenous |
| Subject | PF-03716539 | Unknown | 3 mg | Oral |
| Subject | PF-03716539 | Unknown | 10 mg | Oral |
| Subject | PF-03716539 | Unknown | 25 mg | Oral |
| Subject | PF-03716539 | Unknown | 50 mg | Oral |
| Subject | PF-03716539 | Unknown | 100 mg | Oral |
| Subject | PF-03716539 | Unknown | 200 mg | Oral |
Indications
No indication recorded.